Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flurandrenolide acetate is a synthetic fluorinated corticosteroid primarily used topically to alleviate inflammatory and pruritic manifestations of various corticosteroid-responsive dermatoses. Its therapeutic action stems from its ability to bind to specific cytoplasmic glucocorticoid receptors within target cells. This binding initiates a cascade of events, including the translocation of the receptor-drug complex into the cell nucleus, where it modulates gene expression. This leads to anti-inflammatory effects by stabilizing cellular and lysosomal membranes, inhibiting phospholipase A2, and consequently reducing the biosynthesis of prostaglandins and leukotrienes. Additionally, it exhibits antipruritic effects by stabilizing mast cells and vasoconstrictive properties, which help reduce erythema and edema in inflamed tissues. It is available in various topical formulations such as creams, ointments, lotions, and tapes, with varying potencies depending on the formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Flurandrenolide acetate.